Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 10/20 | 0.51 |
| ▸ | KRAS | P01116 | 1/20 | 0.46 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23631591 | 0.92 | NTSR1 (0.43) | NTSR1KRASHDAC2MMEACHE | |
| SCHEMBL23631588 | 0.88 | KRAS (0.56) | NTSR1KRAS | |
| SCHEMBL23631701 | 0.81 | KRAS (0.46) | KRASPKMSMN1; SMN2L3MBTL1 | |
| SCHEMBL23631632 | 0.77 | NTSR1 (0.67) | NTSR1 | |
| SCHEMBL23631570 | 0.76 | KDM4E (0.52) | NTSR1SMN1; SMN2 | |
| SCHEMBL23631647 | 0.75 | NTSR1 (0.68) | NTSR1 | |
| SCHEMBL3184801 | 0.74 | KRAS (0.55) | KRAS | |
| SCHEMBL23631648 | 0.74 | NTSR1 (0.60) | NTSR1KRASPKM | |
| SCHEMBL23631593 | 0.73 | KDM4E (0.49) | NTSR1SMN1; SMN2 | |
| SCHEMBL6138108 | 0.73 | KMT2A (0.69) | NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214359-A1 | Compounds and Methods for Treating Bacterial Infections | UNIV NEW YORK (US) | 2021-07-15 | — | — | US | claimed |
| US-20210214359-A1 | Compounds and Methods for Treating Bacterial Infections | UNIV NEW YORK (US) | 2021-07-15 | — | — | US | disclosed |
| US-20210214359-A1 | Compounds and Methods for Treating Bacterial Infections | UNIV NEW YORK (US) | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214359-A1 | Compounds and Methods for Treating Bacterial Infections | CBS, MPO, QSOX1 | NTSR1 2656/4885KRAS 1973/4885SERPINE1 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.